NuvalentNUVL
About: Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Employees: 162
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $23.4M | Put options by funds: $16.1M
8% more funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 13 (+1) [Q1 2025]
1.15% more ownership
Funds ownership: 107.56% [Q4 2024] → 108.71% (+1.15%) [Q1 2025]
8% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 72
5% less funds holding
Funds holding: 214 [Q4 2024] → 203 (-11) [Q1 2025]
8% less capital invested
Capital invested by funds: $5.52B [Q4 2024] → $5.1B (-$425M) [Q1 2025]
29% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 35
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
UBS David Dai | 36%upside $100 | Buy Upgraded | 14 Mar 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 49%upside $110 | Buy Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 3 articles about NUVL published over the past 30 days









